NCT01565200View on ClinicalTrials.gov

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2022

Conditions
HER-2 Positive Breast Cancer
Interventions
DRUG

T-DM1

3.6 mg/kg iv every 3 weeks

PROCEDURE

89Zr-trastuzumab

Injection of 89Zr-trastuzumab for HER2 imaging

Trial Locations (5)

1000

Institut Jules Bordet, Brussels

2650

Universitair Ziekenhuis Antwerpen (UZA), Antwerp

1081HV

Vrije Universiteit Amsterdam (VUMC), Amsterdam

9700RB

University Medical Center Groningen (UMCG), Groningen

6525 GA

Radboud University Medical Centre Nijmegen (UMCN), Nijmegen

Sponsors
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Jules Bordet Institute

OTHER